Results 231 to 240 of about 274,980 (287)

Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First-Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries. [PDF]

United European Gastroenterol J
Schreiber S, Walsh A, Hur P, Panattoni L, Hauber B, Land N, Coulter J, Gahlon G, Wosik K, Cappelleri JC, Maravic MC, Guo X, Buisson A.   +12 more
europepmc   +1 more source

Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study. [PDF]

Pain Manag
Ashina M, McAllister P, Gaul C, Leyva-Rendon A, Ramirez LM, Nalpas C, Thiry A, Abraham L, Fountaine RJ, Fullerton T.   +9 more
europepmc   +1 more source

Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in Italy. [PDF]

Neurol Sci
Barbanti P, Tassorelli C, Vernieri F, De Cesaris F, De Icco R, Di Lorenzo C, Finocchi C, Grazzi L, Guerzoni S, Mampreso E, Mastronuzzi T, Messina R, Ornello R, Rao R, Taddeo D, De Tommaso M, Rainero I.   +16 more
europepmc   +1 more source

Updated profiling of COVID-19 vaccine adverse events using VAERS case reports. [PDF]

Front Pharmacol
He A, Hur K, Li X, Zheng J, Hur J, He Y.
europepmc   +1 more source

Brief von Gustav Pfizer an Adelbert von Chamisso

Pfizer, Gustav
core  

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants.

JAMA Netw Open
Rick AM, Deese J, Kerr JE, Hui J, Liu H, Yu G, Chang CH, Fazio N, Tahir MH, Bieltz R, Ravindra A, Megli C, Jeyabalan A, Pugh SJ, Patel D, Fan R, Atwell JE, Cané A, Martin JM.   +18 more
europepmc   +1 more source

Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.

JAMA Dermatol
Adiri R, Gauthier G, Kurosky SK, Sadrarhami M, Bell G, Fiasconaro M, Zhou Y, Rosmarin D, Elbuluk NM, Pandya AG, Hamzavi I.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cefoperazone (Cefobid, Pfizer)

Drug Intelligence & Clinical Pharmacy, 1983
Cefoperazone is a new β-lactam antibiotic that possesses a broad spectrum of activity against gram-positive and gram-negative organisms. Cefoperazone differs from all previous cephalosporins in that it has exceptional activity against P. aeruginosa. The other distinguishing feature of cefoperazone is its high rate of biliary excretion, which will allow
Eric A. Jackson, Alex A. Cardoni, James A. Lyon   +2 more
openaire   +2 more sources

Valuation of Pfizer

2016
exaly   +2 more sources